Jason Coloma, Maze Therapeutics CEO
January 7, 2025 05:36 PM EST
Financing
Startups

Maze files for first biotech IPO of 2025, fol­low­ing $115M fund­ing boost

Kyle LaHucik

Senior Reporter

Maze Ther­a­peu­tics has sub­mit­ted its pitch for an ini­tial pub­lic of­fer­ing af­ter dis­clos­ing a $115 mil­lion Se­ries D …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Up­dat­ed: Bay Area biotech VC to shut down 15 months af­ter launch, sources say, af­ter key in­vestor pulls out

Ma­jor FDA staff cuts would slow drug re­views, ex­perts say

Bris­tol My­ers prunes pipeline amid new round of cost cuts

Trump 2.0 blog: Thou­sands of fed­er­al health work­ers could get axed, ac­cord­ing to re­ports

Up­dat­ed: Lil­ly posts 45% sales jump, culls four pro­grams across obe­si­ty, Alzheimer's, heart fail­ure and eczema

Sen­a­tors ask FDA to dig in­to 'mis­lead­ing' Su­per Bowl ad from Hims

A service from the Financial Times